DON‐Loaded Nanodrug‐T Cell Conjugates With PD‐L1 Blockade for Solid Tumor Therapy
Advanced Science · 2025
DOI: 10.1002/advs.202501815 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Xin Yang und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, T-Lymphocytes, Neoplasms, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Commission - Higher Education Institution Stability Support Plan, Shenzhen Medical Research Fund.
Abstract (Originalsprache)
Adoptive T‐cell therapy (ACT) holds significant promise for treating solid tumors but is often constrained by insufficient T‐cell infiltration, survival, and functional persistence. To overcome these obstacles, we developed DON‐loaded nanodrug‐T cell conjugates with PD‐L1 blockade, forging a dynamic mutualistic relationship between T cells and therapeutic agents. Sustained release of glutamine antagonist 6‐diazo‐5‐oxo‐L‐norleucine (DON) within these conjugates continuously enhances T‐cell endurance and potency by promoting memory differentiation and elevating crucial adhesion and motility genes. Concurrently, PD‐L1 blocking peptides liberate T cells from immunosuppression, assisting T cells with precision toward tumor sites. This dual‐targeting strategy—T cells directed at tumor antigens and peptides at PD‐L1— enriches the tumor microenvironment with potent therapeutics, amplifying T cell‐driven tumor destruction. Our approach effectively overcomes the critical barriers of ACT—infiltration, persistence, and efficacy—unlocking the full therapeutic potential of T‐cell therapy against complex solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China.
Förderung
- National Natural Science Foundation of China
- Shenzhen Science and Technology Innovation Commission - Higher Education Institution Stability Support Plan
- Shenzhen Medical Research Fund
- Fundamental Research Funds for the Central Universities, Sun Yat-sen University
- Guangdong Basic and Applied Basic Research Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Yang, X., Niu, X., Su, Y., Ye, X., Li, W., Zeng, W., Zhao, X., He, Z., Dong, Q., Zhou, X., Sui, X., Chen, G., Gao, Y., & Liu, J. (2025). DON‐Loaded Nanodrug‐T Cell Conjugates With PD‐L1 Blockade for Solid Tumor Therapy. Advanced Science. https://doi.org/10.1002/advs.202501815
Vancouver
Yang X, Niu X, Su Y, Ye X, Li W, Zeng W, et al. DON‐Loaded Nanodrug‐T Cell Conjugates With PD‐L1 Blockade for Solid Tumor Therapy. Advanced Science. 2025. doi:10.1002/advs.202501815
BibTeX
@article{Yang2025,
author = {Yang, Xin and Niu, Xiaoshuang and Su, Ye and Ye, Xiaoyun and Li, Wanqiong and Zeng, Wenxuan and Zhao, Xin and He, Zhuoying and Dong, Qingyu and Zhou, Xiuman and Sui, Xinghua and Chen, Guanyu and Gao, Yanfeng and Liu, Juan},
title = {DON‐Loaded Nanodrug‐T Cell Conjugates With PD‐L1 Blockade for Solid Tumor Therapy},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202501815}
}
EUVIMED